Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.04.24	Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement (EN, Eli Lilly)
11.04.24	Roche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection (RTTNews)
13.03.24	Eli Lilly Strikes Deal With Amazon Pharmacy To Deliver Prescription Drugs (RTTNews)
11.03.24	Eli Lilly Stock Drops 4% (RTTNews)
11.03.24	Lilly: Majority Of People With AD & Skin Of Color Experienced Skin Improvement In Lebrikizumab Study (RTTNews)
08.03.24	FDA Delays Decision On Lilly's Alzheimer's Drug (RTTNews)
21.02.24	Jazz Pharma Names Eli Lilly's Philip Johnson CFO, Effective March 1 (RTTNews)
06.02.24	Eli Lilly Q4 Results Top Estimates (RTTNews)
06.02.24	Eli Lilly Guides FY24 Revenues Above Estimates - Update (RTTNews)
06.02.24	Eli Lilly And Co. Q4 Profit Increases, beats estimates (RTTNews)
30.01.24	HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong (RTTNews)
04.01.24	Eli Lilly Launches LillyDirect To Help Patients Manage Health, Access Medicines (RTTNews)
02.01.24	Lilly to Participate in J.P. Morgan Healthcare Conference (PR Newswire)
28.12.23	Innovent Biologics, Xuanzhu Collaborate On Clinical Trial For Advanced Solid Tumors In China (RTTNews)
27.12.23	Lilly Acquires Point Biopharma For Approx. $1.4 Bln (RTTNews)
27.12.23	Lilly Completes Acquisition of POINT Biopharma (PR Newswire)
18.12.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 (PR Newswire)
12.12.23	Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting (PR Newswire)
11.12.23	Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks (PR Newswire)
08.12.23	Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend (PR Newswire)
05.12.23	Eli Lilly To Present Final Survival Results Of MONARCH 3 Trial Of Verzenio In Breast Cancer (RTTNews)
05.12.23	Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer S... (PR Newswire)
05.12.23	Eli Lilly Announces Availability Of Zepbound In U.S. Pharmacies - Quick Facts (RTTNews)
05.12.23	Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity (PR Newswire)
04.12.23	Lilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisition (RTTNews)
04.12.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 (PR Newswire)
02.12.23	Lilly's Jaypirca Gets Second Approval From FDA (RTTNews)
01.12.23	Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Thera... (PR Newswire)
28.11.23	Lilly To Open New Gateway Labs Location In Partnership With Alexandria Real Estate Equities (RTTNews)
28.11.23	Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego (PR Newswire)
28.11.23	Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego (PR Newswire)
17.11.23	Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany (RTTNews)
17.11.23	Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany (PR Newswire)
17.11.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 (PR Newswire)
15.11.23	Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma (RTTNews)
14.11.23	Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma (PR Newswire)
14.11.23	Lilly to Participate in Evercore ISI HealthCONx Conference (PR Newswire)
09.11.23	Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16 (RTTNews)
09.11.23	Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity (RTTNews)
08.11.23	Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma (PR Newswire)
08.11.23	FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems (PR Newswire)
02.11.23	Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting (PR Newswire)
02.11.23	Eli Lilly Cuts Annual Earnings Outlook Below View - Update (RTTNews)
02.11.23	Eli Lilly And Co. Q3 Earnings Summary (RTTNews)
02.11.23	Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity (PR Newswire)
01.11.23	Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease (PR Newswire)
01.11.23	Lilly Declares Fourth-Quarter 2023 Dividend (PR Newswire)
27.10.23	FDA Approves Lilly's Omvoh For Ulcerative Colitis Treatment (RTTNews)
27.10.23	FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
26.10.23	Lilly to Participate in UBS Biopharma Conference 2023 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:02		Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet
16:02		S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet
16:02		S&P 500-Wert Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 5 Jahren abgeworfen
14.04.25		Pfizer-Aktie dennoch fester: Entwicklung von Abnehmpille gestoppt
14.04.25		DAX 40-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor 3 Jahren eingebracht
14.04.25		SMI-Papier Novartis-Aktie: Wäre eine Novartis-Investition von vor einem Jahr rentabel gewesen?
14.04.25		Neue Analyse: Jefferies & Company Inc. bewertet Bayer-Aktie mit Hold
14.04.25		Erste Schätzungen: Pfizer stellt Ergebnisse des abgelaufenen Quartals vor

16:02

Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet

16:02

S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet

16:02

S&P 500-Wert Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 5 Jahren abgeworfen

14.04.25

Pfizer-Aktie dennoch fester: Entwicklung von Abnehmpille gestoppt

14.04.25

DAX 40-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor 3 Jahren eingebracht

14.04.25

SMI-Papier Novartis-Aktie: Wäre eine Novartis-Investition von vor einem Jahr rentabel gewesen?

14.04.25

Neue Analyse: Jefferies & Company Inc. bewertet Bayer-Aktie mit Hold

14.04.25

Erste Schätzungen: Pfizer stellt Ergebnisse des abgelaufenen Quartals vor

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	89.10	3.05 %	K V
Part Grp Hldg	1’084.50	2.75 %	K V
Zurich Insur Gr	553.60	2.52 %	K V
Swiss Life Hldg	775.80	2.43 %	K V
Geberit	559.60	2.15 %	K V
Sonova Hldg	234.00	-0.68 %	K V
CieFinRichemont	135.80	-0.88 %	K V
UBS Group	23.20	-1.11 %	K V
Swiss Re	139.80	-1.48 %	K V
Logitech Intl	59.66	-1.71 %	K V

Eli Lilly Aktie VALOR 947556 / ISIN US5324571083

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten